Search Results
Jan 23, 2026, 15:24 ET Statement from Dr. Larry Schlesinger, President & CEO, Texas Biomedical Research Institute
tuberculosis and lung biology. TB is the deadliest infectious disease in the world.About Texas Biomedical Research InstituteTexas Biomedical Research
More news about: Texas Biomedical Research Institute
Jan 22, 2026, 12:30 ET Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that the key results from the Phase 2b CORAL trial of oral nalbuphine ER
More news about: Trevi Therapeutics, Inc.
Jan 22, 2026, 10:22 ET Florida Cancer Specialists & Research Institute Among First in Florida to Trial Next-Generation Immunotherapy for Castration-Resistant Prostate Cancer
trial. FCS offers step-up dosing and maintenance therapy with FDA-approved bispecific drugs to treat recurring and resistant blood cancers and small cell lung cancer."Treatment-resistant cancers pose a major challenge in medicine," said
More news about: Florida Cancer Specialists & Research Institute
Jan 22, 2026, 09:58 ET New Report: States Should Increase Tobacco Taxes to Reduce Tobacco Use and Raise Revenue to Fund Critical Public Health Programs
Program."The report was released by the Campaign for Tobacco-Free Kids, American Cancer Society Cancer Action Network, American Heart Association, American Lung Association, Americans for Nonsmokers' Rights, and Truth Initiative.
More news about: Campaign for Tobacco-Free Kids
Jan 22, 2026, 08:13 ET Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
development.Oncology Context and Unmet NeedEGFR inhibitors are cornerstone therapies across multiple major cancer indications, including lung, colorectal, and head-and-neck cancers. However, treatment-related toxicity and symptom burden remain among the most common and dose-limiting challenges,
More news about: Hoth Therapeutics, Inc.
Jan 22, 2026, 08:00 ET CVS Health® makes health insurance simpler and more affordable for Americans
lung, breast, and prostate cancer to cover whole pathways of current and future screenings. We then built on this streamlining momentum
More news about: CVS Health
Jan 21, 2026, 10:00 ET Medlive Expands Advisory Board with Three Leading Oncology Experts
include novel drug development, antibody-drug conjugates, immunotherapy, and metabolic therapies for lung cancer. Dr. Lisberg has collaborated with MedliveCME since 2020 on educational initiatives addressing lung cancer therapeutics and clinical trial access. Dr. Lisberg's work has been published in leading
More news about: Medlive
Jan 21, 2026, 09:50 ET Americans Are Struggling to Tell Allergy and Illness Symptoms Apart This Holiday Season, LifeBridge Experts Say
quail eggs to naturally support healthy histamine levels in the body. The brand's IQ AIR is another dietary supplement that naturally supports lung health through a unique blend of vitamins and Cordyceps extract."We're in the business of better breathing through natural solutions," said Ladislav,
More news about: LifeBridge
Jan 21, 2026, 05:03 ET New Lung Association Report Outlines Indoor Air Quality Policies to Make Schools Healthier and More Energy Efficient
Council.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Jan 21, 2026, 03:07 ET Kanazawa University research: Visualizing how cancer drugs reshape proteins linked to lung cancer
-- Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University led have uncovered how targeted lung cancer drugs alter the shape and behavior of a key cancer-driving protein—revealing a hidden mechanism that helps explain why some treatments stop working
More news about: Kanazawa University
Jan 20, 2026, 09:15 ET Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
is also approved to identify adult patients with locally advanced or metastatic rearranged-during-transfection (RET) fusion-positive non-small-cell lung cancer (NSCLC) who may benefit from treatment with Lilly's RETEVMO® (selpercatinib).Use of forward-looking statementsThis release
More news about: Illumina, Inc.
Jan 20, 2026, 08:05 ET American Lung Association Calls on Nation to Stair Climb for Clean Air and Healthy Lungs
21About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Jan 20, 2026, 07:45 ET Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
who progressed on prior mirvetuximab soravtansine. These initial data also indicate a promising tolerability profile with low rates of interstitial lung disease, peripheral neuropathy, and alopecia, and no significant ocular toxicity.Sofetabart mipitecan recently advanced into the Phase 3 FRAmework-01
More news about: Eli Lilly and Company
Jan 20, 2026, 06:00 ET Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis
Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced it was selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD), to provide objective, quantitative HRCT imaging biomarkers
More news about: Brainomix
Jan 18, 2026, 20:00 ET D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
mutations.The newly cleared Phase 2 study will evaluate the combination of D3S‑001 and D3S‑002 in patients with KRAS G12C–mutant non‑small cell lung cancer (NSCLC) who have progressed on prior KRAS G12C‑targeted therapies. The trial, expected to begin in the first half of 2026, will investigate safety,
More news about: D3 Bio
Jan 16, 2026, 11:56 ET Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic
expected to support advanced imaging workflows across a subset of existing presets, including abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Unlike legacy ultrasound systems, Butterfly Network is built on a semiconductor chip using a fully electronic 2D capacitive micromachined
More news about: USA News Group
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
targets at once. This secular transition is creating massive opportunities for specialized platforms that can scale across high-prevalence killers like lung, breast, and pancreatic cancers, led by GT Biopharma, Inc. (NASDAQ: GTBP), ImmunityBio (NASDAQ: IBRX), Erasca, Inc. (NASDAQ: ERAS),
More news about: Equity Insider
Jan 16, 2026, 08:00 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
Accelerated approval for perioperative treatment of gastric cancer in China;U.S. BLA filings for extensive-stage and limited-stage small cell lung cancer (ES-SCLC and LS-SCLC);Approval of various indications in the EU;Completion of enrolment and achievement of primary endpoints
More news about: Henlius
Jan 15, 2026, 20:00 ET Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
): A global first-in-class ALPPL2 x CD3 targeted TCE being developed for the treatment of gynecologic tumor, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. The Company has nominated a preclinical candidate (PCC) in January 2026.Additional TCE programs
More news about: Antengene Corporation Limited
Jan 15, 2026, 19:00 ET JPM 2026 | 科倫博泰CEO葛均友博士全面展示公司創新成果及未來發展戰略
DC 藥物研發管線，並將適應症進一步拓展至非腫瘤領域。過去一年，科倫博泰有多項研究成果亮相國際學術會議並發表於權威期刊：3 項入選美國臨床腫瘤學會（ASCO）口頭報告、3 項入選歐洲腫瘤內科學會（ESMO）最新突破性摘要（LBA）並作口頭報告。其中，蘆康沙妥珠單抗 OptiTROP-Lung04 研究（針對 TKI 治療後進展的 EGFR 突變非小細胞肺癌（NSCLC））結果在 ESMO 主席論壇環節重磅發布，並同步發表於《新英格蘭醫學雜誌》，彰顯其在全球範圍內的學術與臨床價值。而在商業化層面，科倫博泰已形成具有競爭力的首批產品矩陣。核心產品 TROP2 ADC 蘆康沙妥珠單抗在中國獲批 3
More news about: 科倫博泰
Jan 15, 2026, 15:42 ET ISEA Applauds Trump Administration for Reinstating NIOSH Staff, Preserving Critical Worker Safety Programs
mining. Research focuses on both the physical practices of mining and personal protective equipment for miners. The mining program also conducts Black Lung health screenings for coal miners.Commercial fishing safety research: Based in Spokane, WA and Anchorage, AK, The program improves commercial
More news about: International Safety Equipment Association (ISEA)
Jan 15, 2026, 13:30 ET Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference
breast cancer and lung cancer indications. Additionally, nine uniquely designed ADC and novel DC drugs—including cutting-edge directions such as bispecific ADC and radiopharmaceutical conjugate (RDC) are in clinical stage. For high-incidence tumor types in China, such as breast cancer, lung cancer, and gastrointestinal
More news about: Kelun-Biotech
Jan 15, 2026, 12:27 ET /C O R R E C T I O N -- Brayton Purcell LLP/
Silicosis is a fatal and incurable lung disease caused by inhaling respirable crystalline silica dust. Workers fabricating artificial stone countertops face extreme risk because crystalline
More news about: Brayton Purcell LLP
Jan 15, 2026, 11:05 ET LEADOPTIK Announces FDA Clearance of the LIA™ for Lung Biopsy Procedures
(LIA) system, the world's first system to use silicon photonics imaging technology and software designed to improve the accuracy of lung biopsy procedures. Lung cancer remains the leading cause of cancer-related death worldwide, claiming approximately 1.8 million lives each year, more than the
More news about: LEADOPTIK
Jan 15, 2026, 10:43 ET Cancer Biomarkers Market Surges to USD 45.7 Billion by 2033, Propelled by 8.6% CAGR - Verified Market Reports®
harmonized regulatory standards across major markets. Western European countries demonstrate high adoption of companion diagnostics, particularly in breast, lung, and colorectal cancers. Government-supported cancer screening programs and cross-border research initiatives continue to reinforce regional demand.Asia-Pacific
More news about: Verified Market Reports